AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21600518 — intervention group
Group type: COMPARATOR
Intervention: Control (no specific intervention mentioned)
Number of subjects: 134
Study 17976942 — intervention group
Group type: EXPERIMENTAL
Intervention: Scirrhous HCC
Number of subjects: 317
Study 17976942 — intervention group
Group type: COMPARATOR
Intervention: Usual HCC
Number of subjects: 317
Study 17976942 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups after curative resection
Number of subjects: 317
Study 17908726 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Buddies program (2‐3 hours/week for 21 weeks)
Number of subjects: 383
Study 17908726 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 383
Study 15476624 — intervention group
Group type: EXPERIMENTAL
Intervention: Abciximab-coated stents
Number of subjects: 0
Study 15476624 — intervention group
Group type: COMPARATOR
Intervention: Control stents
Number of subjects: 0
Study 11721808 — intervention group
Group type: EXPERIMENTAL
Intervention: MR urography with contrast medium administration
Number of subjects: 20
Study 11721808 — intervention group
Group type: EXPERIMENTAL
Intervention: MR renograms
Number of subjects: 20
Study 11721808 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast medium administration
Number of subjects: 20
Study 11721808 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual determination of hydronephrosis
Number of subjects: 20
Study 11721808 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual determination of unilateral delayed excretion of contrast material
Number of subjects: 20
Study 9805722 — intervention group
Group type: EXPERIMENTAL
Intervention: New antenatal care (ANC) programme consisting of tests, clinical procedures, and follow-up actions
Number of subjects: 24000
Study 9805722 — intervention group
Group type: COMPARATOR
Intervention: Traditional programme currently in use (control group)
Number of subjects: 24000
Study 9805722 — intervention group
Group type: EXPERIMENTAL
Intervention: New antenatal care (ANC) programme
Number of subjects: 24000
Study 8728911 — intervention group
Group type: EXPERIMENTAL
Intervention: 10mg diazepam administered intravenously
Number of subjects: 60
Study 8728911 — intervention group
Group type: COMPARATOR
Intervention: Control group (no diazepam)
Number of subjects: 60
Study 2654259 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 325 mg daily (N = 37)
Number of subjects: 70
Study 2654259 — intervention group
Group type: COMPARATOR
Intervention: Control group (N = 33)
Number of subjects: 70
Study 799565 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendrofluazide
Number of subjects: 18000
Study 799565 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 18000
Study 799565 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 18000
Study 799565 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial workload
Number of subjects: 18000
Study 799565 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological effects
Number of subjects: 18000
Study 799565 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost of full-scale trial
Number of subjects: 18000
Study 31712768 — intervention group
Group type: EXPERIMENTAL
Intervention: spring milk fat
Number of subjects: 172
Study 31712768 — intervention group
Group type: COMPARATOR
Intervention: vegetable fat
Number of subjects: 172
Study 31712768 — intervention group
Group type: EXPERIMENTAL
Intervention: winter milk fat
Number of subjects: 172
Study 31712768 — intervention group
Group type: EXPERIMENTAL
Intervention: winter milk fat supplemented with calcium
Number of subjects: 172
Study 31229734 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-face communication partner training
Number of subjects: 55
Study 31229734 — intervention group
Group type: EXPERIMENTAL
Intervention: Telepractice communication partner training
Number of subjects: 55
Study 27056549 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated care and participatory workplace intervention
Number of subjects: 150
Study 27056549 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 150
Study 25488124 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept (2.0 mg)
Number of subjects: 38
Study 25488124 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab (0.5 mg)
Number of subjects: 38
Study 25488124 — intervention group
Group type: COMPARATOR
Intervention: Control group (22 age- and sex-matched healthy patients)
Number of subjects: 38
Study 22730366 — intervention group
Group type: EXPERIMENTAL
Intervention: secukinumab 25 mg, 75 mg, 150 mg, 300 mg
Number of subjects: 237
Study 22730366 — intervention group
Group type: EXPERIMENTAL
Intervention: secukinumab 75 mg, 150 mg, 300 mg
Number of subjects: 237
Study 22730366 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 237
Study 21255083 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole
Number of subjects: 2507
Study 21255083 — intervention group
Group type: EXPERIMENTAL
Intervention: Praziquantel
Number of subjects: 2507
Study 21255083 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2507
Study 19953901 — intervention group
Group type: EXPERIMENTAL
Intervention: Drainage
Number of subjects: 30
Study 19953901 — intervention group
Group type: COMPARATOR
Intervention: No Drainage
Number of subjects: 30
Study 16501017 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training (5 sessions/week for 2 weeks at 70-80% of maximal HR)
Number of subjects: 95
Study 16501017 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training
Number of subjects: 95
Study 16501017 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline and post-endurance training
Number of subjects: 95
Study 15053124 — intervention group
Group type: EXPERIMENTAL
Intervention: Outreach nurse support consisting of three telephone contacts and one home visit within six months after discharge.
Number of subjects: 173
Study 15489091 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal insufficiency categorized as creatinine clearance (CrCl) 40 to 60 ml/min
Number of subjects: 702
Study 15489091 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal insufficiency categorized as creatinine clearance (CrCl) <40 ml/min
Number of subjects: 702
Study 15489091 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitors (users)
Number of subjects: 702
Study 15489091 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitors (nonusers)
Number of subjects: 702
Study 15489091 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal insufficiency
Number of subjects: 702
Study 10699806 — intervention group
Group type: EXPERIMENTAL
Intervention: Endolymphatic shunt procedure
Number of subjects: 30
Study 10699806 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 9120174 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary coronary angioplasty
Number of subjects: 95
Study 9120174 — intervention group
Group type: COMPARATOR
Intervention: Thrombolytic therapy
Number of subjects: 95
Study 8227798 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril, 10 mg twice daily (n = 20)
Number of subjects: 32
Study 8227798 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 12)
Number of subjects: 32
Study 2876723 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg levocabastine
Number of subjects: 12
Study 2876723 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg disodium cromoglycate (DSCG)
Number of subjects: 12
Study 2876723 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 2786751 — intervention group
Group type: EXPERIMENTAL
Intervention: Monoclonal antibody 260F9‐recombinant ricin A chain (10 micrograms/kg daily)
Number of subjects: 4
Study 2786751 — intervention group
Group type: EXPERIMENTAL
Intervention: Monoclonal antibody 260F9‐recombinant ricin A chain (50 micrograms/kg daily)
Number of subjects: 4
Study 2786751 — intervention group
Group type: EXPERIMENTAL
Intervention: Monoclonal antibody 260F9‐recombinant ricin A chain (10 micrograms/kg and 50 micrograms/kg)
Number of subjects: 4
Study 2786751 — intervention group
Group type: EXPERIMENTAL
Intervention: Monoclonal antibody 260F9‐recombinant ricin A chain (50 micrograms/kg)
Number of subjects: 4
Study 31050956 — intervention group
Group type: EXPERIMENTAL
Intervention: Light therapy (Bioptron)
Number of subjects: 52
Study 31050956 — intervention group
Group type: COMPARATOR
Intervention: Control (exercises and cryotherapy)
Number of subjects: 52
Study 28914415 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin loading doses (1.5 times the maintenance dose for 3 days followed by pre‐procedural warfarin maintenance dosing)
Number of subjects: 39
Study 28914415 — intervention group
Group type: COMPARATOR
Intervention: Warfarin maintenance doses
Number of subjects: 39
Study 28914415 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin loading doses
Number of subjects: 39
Study 25548331 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccination reminder 'on'
Number of subjects: 8481
Study 25548331 — intervention group
Group type: COMPARATOR
Intervention: Vaccination reminder 'off'
Number of subjects: 8481
Study 25548331 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccination reminder 'on' in winter
Number of subjects: 8481
Study 25548331 — intervention group
Group type: COMPARATOR
Intervention: Vaccination reminder 'off' in winter
Number of subjects: 8481
Study 25548331 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccination reminder 'on' in fall
Number of subjects: 8481
Study 25548331 — intervention group
Group type: COMPARATOR
Intervention: Vaccination reminder 'off' in fall
Number of subjects: 8481
Study 23429258 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid withdrawal (SW)
Number of subjects: 30
Study 23429258 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid withdrawal (SW) in prepubertal patients
Number of subjects: 30
Study 23429258 — intervention group
Group type: COMPARATOR
Intervention: Steroid control (SC)
Number of subjects: 30
Study 21827932 — intervention group
Group type: EXPERIMENTAL
Intervention: Sericite belt (experimental group)
Number of subjects: 104
Study 21827932 — intervention group
Group type: COMPARATOR
Intervention: Placebo belt (control group)
Number of subjects: 104
Study 21827932 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (experimental and control)
Number of subjects: 104
Study 18990373 — intervention group
Group type: EXPERIMENTAL
Intervention: P vaginal ring
Number of subjects: 20
Study 18990373 — intervention group
Group type: COMPARATOR
Intervention: Vaginal gel
Number of subjects: 20
Study 17264421 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise
Number of subjects: 72
Study 17264421 — intervention group
Group type: EXPERIMENTAL
Intervention: Stretching
Number of subjects: 72
Study 17264421 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 72
Study 14575730 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg T enanthate
Number of subjects: 25
Study 14575730 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 25
Study 11833925 — intervention group
Group type: EXPERIMENTAL
Intervention: Incredible Years Parenting Program (8-12 weeks of weekly 2-hour parenting classes)
Number of subjects: 634
Study 11833925 — intervention group
Group type: COMPARATOR
Intervention: Regular Head Start Program without parenting groups
Number of subjects: 634
Study 9727892 — intervention group
Group type: EXPERIMENTAL
Intervention: T600/G12 (troglitazone 600 mg + glyburide 12 mg)
Number of subjects: 552
Study 11271239 — intervention group
Group type: EXPERIMENTAL
Intervention: FK 506 therapy
Number of subjects: 545
Study 11271239 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporin A therapy
Number of subjects: 545
Study 2736113 — intervention group
Group type: EXPERIMENTAL
Intervention: Instrumental anastomosis
Number of subjects: 113
Study 2736113 — intervention group
Group type: COMPARATOR
Intervention: Manual anastomosis
Number of subjects: 113
Study 2736113 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 113
Study 4694404 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary treatment alone
Number of subjects: 200
Study 4694404 — intervention group
Group type: COMPARATOR
Intervention: Oral hypoglycaemic drugs
Number of subjects: 200
Study 30635177 — intervention group
Group type: EXPERIMENTAL
Intervention: REFOCUS‐PULSAR intervention
Number of subjects: 942
Study 30635177 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 942
Study 28330586 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured Nintendo Wii protocol (n=8)
Number of subjects: 14
Study 28330586 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (n=6)
Number of subjects: 14
Study 26395298 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidomain intervention to prevent disability in elders (MINDED)
Number of subjects: 0
Study 26395298 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 26060625 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel 0.75 mg given 12 hours apart
Number of subjects: 529
Study 26060625 — intervention group
Group type: COMPARATOR
Intervention: Yuzpe regimen (ethinyl estradiol 100 μg plus 0.5 mg Levonorgestrel repeated after 12 hours)
Number of subjects: 529
Study 21705296 — intervention group
Group type: EXPERIMENTAL
Intervention: Palpation by a sports medicine board‐certified staff physician
Number of subjects: 25
Study 21705296 — intervention group
Group type: EXPERIMENTAL
Intervention: Palpation by a sports medicine fellow
Number of subjects: 25
Study 21705296 — intervention group
Group type: EXPERIMENTAL
Intervention: Palpation by a physical medicine and rehabilitation resident
Number of subjects: 25
Study 20055196 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 259
Study 20055196 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl
Number of subjects: 259
Study 20055196 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 259
Study 20055196 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam plus Fentanyl
Number of subjects: 259
Study 20055196 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam plus Ketamine
Number of subjects: 259
Study 20055196 — intervention group
Group type: COMPARATOR
Intervention: Drug-free group (Control)
Number of subjects: 259
Study 16960118 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic oligosaccharide-protein conjugate vaccine, administered as a single intramuscular injection.
Number of subjects: 0
Study 16960118 — intervention group
Group type: COMPARATOR
Intervention: Control vaccine, details not specified.
Number of subjects: 0
Study 15574080 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 days of training abstinence
Number of subjects: 25
Study 15574080 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 days of training abstinence
Number of subjects: 25
Study 15574080 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 days of training abstinence
Number of subjects: 25
Study 15574080 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 days of training abstinence
Number of subjects: 25
Study 11560221 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol-N2O (P/N)
Number of subjects: 108
Study 11560221 — intervention group
Group type: EXPERIMENTAL
Intervention: Total intravenous anesthesia using propofol (P/P)
Number of subjects: 108
Study 11560221 — intervention group
Group type: COMPARATOR
Intervention: Thiopental-N2O (T/N)
Number of subjects: 108
Study 9586883 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen A: MTX 1,000 mg/m2 i.v. infused over 24 hours and MP 1,000 mg/m2 i.v. infused over 6 hours
Number of subjects: 1304
Study 9586883 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen B: Low-dose repetitive MTX 30 mg/m2 orally every 6 hours for six doses and i.v. MP
Number of subjects: 1304
Study 9586883 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen C: i.v. MTX alone
Number of subjects: 1304
Study 9586883 — intervention group
Group type: EXPERIMENTAL
Intervention: CNS prophylaxis: age‐adjusted intrathecal MTX (ITM) changed to age‐adjusted triple intrathecal therapy (TIT)
Number of subjects: 1304
Study 7821009 — intervention group
Group type: EXPERIMENTAL
Intervention: Taktosan Salbe (water-in-oil emulsion)
Number of subjects: 10
Study 7821009 — intervention group
Group type: EXPERIMENTAL
Intervention: RAWI Speerschutzcreme (oil-in-water emulsion)
Number of subjects: 10
Study 7821009 — intervention group
Group type: COMPARATOR
Intervention: Control (irritant only, no BC-pretreatment)
Number of subjects: 10
Study 3280257 — intervention group
Group type: EXPERIMENTAL
Intervention: Cephalexin 500 mg po, qid for three extra days (Group A)
Number of subjects: 200
Study 3280257 — intervention group
Group type: COMPARATOR
Intervention: No oral therapy (Group B)
Number of subjects: 200
Study 3280257 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall infection rate
Number of subjects: 200
Study 3280257 — intervention group
Group type: EXPERIMENTAL
Intervention: Median sternotomy infection rate
Number of subjects: 200
Study 3280257 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical wound infection rate
Number of subjects: 200
Study 31543078 — intervention group
Group type: EXPERIMENTAL
Intervention: Psilocybin with psychological support
Number of subjects: 0
Study 31543078 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 30768859 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin administration 20 minutes before meal
Number of subjects: 30
Study 30768859 — intervention group
Group type: COMPARATOR
Intervention: Insulin administration 0 minutes before meal
Number of subjects: 30
Study 29032132 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline resting heart rate (HR)
Number of subjects: 1767
Study 29032132 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in HR from the preceding visit
Number of subjects: 1767
Study 29032132 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-updated resting HR at each visit
Number of subjects: 1767
Study 26016586 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral health education video game
Number of subjects: 110
Study 26016586 — intervention group
Group type: COMPARATOR
Intervention: Verbal oral health education
Number of subjects: 110
Study 25239835 — intervention group
Group type: EXPERIMENTAL
Intervention: ATL1102 (200 mg subcutaneously injected 3 times in the first week and twice weekly for 7 weeks)
Number of subjects: 77
Study 25239835 — intervention group
Group type: EXPERIMENTAL
Intervention: ATL1102
Number of subjects: 77
Study 25239835 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study 22826621 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 insufflation
Number of subjects: 60
Study 22826621 — intervention group
Group type: COMPARATOR
Intervention: Air insufflation
Number of subjects: 60
Study 19238693 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant trastuzumab (Herceptin)
Number of subjects: 0
Study 19238693 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 17711151 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular exercise programme
Number of subjects: 160
Study 17711151 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 160
Study 15240438 — intervention group
Group type: EXPERIMENTAL
Intervention: Joint crisis plan intervention
Number of subjects: 160
Study 15240438 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 160
Study 11152433 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxycillin 1 g bd
Number of subjects: 395
Study 11152433 — intervention group
Group type: COMPARATOR
Intervention: Amoxycillin 500 mg tds
Number of subjects: 395
Study 9014544 — intervention group
Group type: EXPERIMENTAL
Intervention: Target-controlled infusion of propofol (4 micrograms.ml‐1 target blood concentration, increased by 2 micrograms.ml‐1 after 3 min of consciousness not lost)
Number of subjects: 90
Study 9014544 — intervention group
Group type: COMPARATOR
Intervention: Manual infusion of propofol at 1200 ml.h‐1
Number of subjects: 90
Study 9014544 — intervention group
Group type: COMPARATOR
Intervention: Manual infusion of propofol at 600 ml.h‐1
Number of subjects: 90
Study 9014544 — intervention group
Group type: EXPERIMENTAL
Intervention: Target-controlled infusion of propofol
Number of subjects: 90
Study 9014544 — intervention group
Group type: COMPARATOR
Intervention: Manual infusion of propofol (both rates)
Number of subjects: 90
Study 7884236 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative pelvic hyperthermochemotherapy (IOPHC) with 40 micrograms/ml mitomycin C at 45 degrees C for 90 min
Number of subjects: 62
Study 7884236 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone (control group)
Number of subjects: 62
Study 7884236 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (IOPHC and control)
Number of subjects: 62
Study 7884236 — intervention group
Group type: EXPERIMENTAL
Intervention: IOPHC treatment
Number of subjects: 62
Study 2448428 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative chemotherapy with high-dose methotrexate (HDMTX) and the triple drug combination of bleomycin, cyclophosphamide, and dactinomycin (BCD)
Number of subjects: 0
Study 2448428 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative chemotherapy with doxorubicin (DOX) and cisplatin (CPDD) for poor responders
Number of subjects: 0
Study 2448428 — intervention group
Group type: COMPARATOR
Intervention: Preoperative chemotherapy with DOX/CPDD
Number of subjects: 0
Study 2448428 — intervention group
Group type: COMPARATOR
Intervention: Postoperative salvage chemotherapy with BCD and CPDD/ifosfamide (IFO)
Number of subjects: 0
Study 2448428 — intervention group
Group type: EXPERIMENTAL
Intervention: Good responders receiving postoperative chemotherapy
Number of subjects: 0
Study 2448428 — intervention group
Group type: COMPARATOR
Intervention: Good responders receiving postoperative chemotherapy in control arm
Number of subjects: 0
Study 2448428 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall study arm
Number of subjects: 0
Study 2448428 — intervention group
Group type: COMPARATOR
Intervention: Overall control arm
Number of subjects: 0
Study 29453445 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (NMDAR antagonist)
Number of subjects: 19
Study 29453445 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19